Abstracts tagged "Clinical research"

Abstract Number: 895 • 2014 ACR/ARHP Annual Meeting
The Fibromyalgia Syndrome and Widespread Pain Frequency in Active Duty U.S. Service Members with Posttraumatic Stress Disorder
Bernard Hildebrand¹, Jay B. Higgs¹, Douglas Williamson², Edna Foa³, Patricia Resick⁴, Jim Mintz², Antoinette Brundige², Kevin Kelly⁵, Adam Borah⁵, Stacey Young-McCaughan², Brett Litz⁶, Elizabeth Hembree³ and Alan Peterson², ¹Rheumatology, San Antonio Military Medical Center, JBSA - Fort Sam Houston, TX, ²The University of Texas Health Science Center at San Antonio, San Antonio, TX, ³University of Pennsylvania, Philadelphia, PA, ⁴Duke University, Durham, NC, ⁵Carl R. Darnall Army Medical Center, Fort Hood, TX, ⁶VA Boston Healthcare System, Boston, MA
Background/Purpose: Posttraumatic stress disorder (PTSD) and pain are common amongst US military service members who have deployed to Iraq and Afghanistan. Studies suggest the co-morbidity…
Abstract Number: 719 • 2014 ACR/ARHP Annual Meeting
Target Modulation of a Type I Interferon (IFN) Gene Signature with Sifalimumab or Anifrolumab in Systemic Lupus Erythematosus (SLE) Patients in Two Open Label Phase 2 Japanese Trials
Chris Morehouse¹, Linda Chang², Liangwei Wang³, Philip Brohawn¹, Shinya Ueda⁴, Gabor Illei⁵, Warren Greth³, Stephen Yoo⁶, Lorin Roskos⁷, Yihong Yao⁸, Gabriel Robbie⁹ and Brandon W. Higgs¹, ¹Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ²Translational Sciences, MedImmune, Hayward, CA, ³MedImmune, LLC, Gaithersburg, MD, ⁴PK, Astrazeneca, Osaka, Japan, ⁵Clinical Development, Medimmune, Gaithersburg, MD, ⁶Clinical Development, MedImmune, LLC, Gaithersburg, MD, ⁷One MedImmune Way, Medimmune, Gaithersburg, MD, ⁸Translational Sciences, MedImmune, Gaithersburg, MD, ⁹Clinical Pharmacology and DMPK, MedImmune, Gaithersburg, MD
Background/Purpose The pharmacokinetic (PK) and pharmacodynamic (PD) effects of two investigational monoclonal antibodies inhibiting type I IFN signaling - sifalimumab or anifrolumab, specific for IFN-α…
Abstract Number: 546 • 2014 ACR/ARHP Annual Meeting
Psoriatic Arthritis Mutilans: Characteristics and Radiographic Progression
Deepak R. Jadon¹, Gavin Shaddick², William Tillett¹, Graham Robinson³, Charlotte Cavill¹, Nicola Waldron¹, Eleanor Korendowych¹ and Neil J McHugh⁴, ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Department of Mathematics, University of Bath, Bath, United Kingdom, ³Royal United Hospital, Bath, United Kingdom, ⁴Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
Background/Purpose: Psoriatic arthritis mutilans (PAM) is a rare extreme subtype of psoriatic arthritis (PsA). Our objectives were to: (1) compare clinical characteristics of PsA patients…
Abstract Number: 545 • 2014 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy of Certolizumab Pegol over 96 Weeks in Patients with Psoriatic Arthritis with and without Prior Tumor Necrosis Factor Inhibitor Exposure
Philip J. Mease¹, Roy Fleischmann², Jurgen Wollenhaupt³, Atul A. Deodhar⁴, Dafna D. Gladman⁵, Bengt Hoepken⁶, Luke Peterson⁷ and Désirée M. van der Heijde⁸, ¹Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA, ²Rheumatology, University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX, ³Division of Reheumatology, Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ⁴Oregon Health and Sciences University, Portland, OR, ⁵University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶UCB Pharma, Monheim, Germany, ⁷Biostatistics US Group, UCB Pharma, Raleigh-Durham, NC, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose Previous reports of RAPID-PsA (NCT01087788) demonstrated efficacy and safety of certolizumab pegol (CZP) over 48 weeks (wks) in psoriatic arthritis (PsA) patients (pts), including…
Abstract Number: 364 • 2014 ACR/ARHP Annual Meeting
In Early Rheumatoid Arthritis, the Multi-Biomarker Disease Activity Score at Different Time-Points Is Predictive of Subsequent Radiographic Progression
Karen Hambardzumyan¹, R.J. Bolce², Saedis Saevarsdottir*³, Kristina Forslind⁴, Ingemar F. Petersson⁵, Pierre Geborek⁶, Eric H. Sasso², David Chernoff², Scott Cruickshank⁷ and Ronald F. van Vollenhoven⁸, ¹ClinTRID, the Karolinska Institute, Stockholm, Sweden, ²Crescendo Bioscience Inc., South San Francisco, CA, ³Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Medicine, Karolinska Institute, Stockholm, Sweden, ⁵Lund University, Lund, Sweden, ⁶Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, ⁷Scott Cruickshank and Associates, Inc., Santa Barbara, CA, ⁸Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden
Background/Purpose The prediction of radiographic progression in early rheumatoid arthritis (eRA) patients is important for optimal treatment. We previously demonstrated that a multi-biomarker disease activity…
Abstract Number: 259 • 2014 ACR/ARHP Annual Meeting
Development of Pediatric Item Banks to Measure Pain Behavior in the Patient Reported Outcomes Measurement Information System
Esi M. Morgan DeWitt¹, Kimberly Barnett², Wen-Hung Chen³, Jennifer Farrell⁴, Dennis Revicki⁵, Adam Carle⁶, Karon Cook⁷, Kenneth Goldschneider⁸, Carlton Dampier⁹, David D. Sherry¹⁰ and Susmita Kashikar-Zuck², ¹Department of Pediatrics, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Evidera, Bethesda, MD, ⁴Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Outcomes Research, Evidera, Bethesda, MD, ⁶Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁷Center for Patient-Centered Outcomes - Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁸Anesthesia, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹Department of Pediatrics (Hematology-Oncology), Emory University School of Medicine, Atlanta, GA, ¹⁰Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose The NIH Patient Reported Outcomes Measurement Information System (PROMIS) has created publicly available patient reported outcomes measures in several domains of physical, social and…
Abstract Number: L15 • 2014 ACR/ARHP Annual Meeting
Remission Induction By Etanercept in Enthesitis Related Arthritis JIA-Patients (juvenile undifferentiated Spondylarthropathy)
Ivan Foeldvari¹, Gerd Horneff², Kirsten Minden³, Ralf Trauzeddel⁴, J B. Kuemmerle-Deschner⁵, Klaus Tenbrock⁶, Gerd Ganser⁷ and Hans-Iko Huppertz⁸, ¹Department of Pediatric Rheumatology, Hamburger Zentrum für Kinder und Jugendrheumatologie, Hamburg, Germany, ²Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ³Chidlrens´ hospital, Charité University Medicine, Berlin, Germany, ⁴Pediatrics, Helios Clinics, Berlin, Germany, ⁵Division of Pediatric Rheumatology, Department of Pediatrics, University Hospital Tuebingen, Tuebingen, Germany, ⁶University Aachen, Aachen, Germany, ⁷Pediatric Rheumatology, Sankt Josef Stift, Sendenhorst, Germany, ⁸Kinderklinik, Krinikum Bremen-Mitte, Bremen, Germany
Background/Purpose: Enthesitis related arthritis (ERA) is a Juvenile Idiopathic Arthritis category, clinically related to the syndrome of undifferentiated spondyloarthropathy in adults. This study is intended…
Abstract Number: 429 • 2013 ACR/ARHP Annual Meeting
Sustained Clinical Efficacy After Multiple Courses of Rituximab in Rheumatoid Arthritis Patients With Inadequate Response to Tumour Necrosis Factor Inhibitors: 2-Year Data From the Repeat (Repeated Courses in Routine Clinical Practice) Study
Catalin Codreanu¹, Ioan Ancuta² and Ruxandra Ionescu³, ¹Rheumatology, “Dr. I. Stoia” Center for Rheumatic Diseases, Bucharest, Romania, ²“Dr. I. Cantacuzino” Hospital, Bucharest, Romania, ³Internal Medicine, Clinic Hospital Sf. Maria, Bucharest, Romania
Background/Purpose: In the last decade, biologic therapy changed dramatically treatment options for rheumatoid arthritis (RA). However, a significant number of patients failed to maintain the…
Abstract Number: L17 • 2013 ACR/ARHP Annual Meeting
Safety and Immunogenicity of Inactivated Varicella-Zoster Virus Vaccine in Adults with Autoimmune Disease
Lawrence McAdam¹, Michael Eberhardson², William Grainger³, Kim Papp⁴, Stephen Hall⁵, Tina Sterling⁶, Jon Stek⁶, Lei Pang⁶, Yanli Zhao⁶, Ivan Chan⁶, Richard Haupt⁶, Janie Parrino⁶ and Jeffrey Silber⁶, ¹Advanced Rheumatology, Infusion and Clinical Research Center, Thousand Oaks, CA, ²Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ³Neurological Physicians of Arizona, Gilbert, AZ, ⁴K. Papp Clinical Research,, Waterloo, ON, Canada, ⁵Emeritus Research, Malvern, Australia, ⁶Merck & Co., Inc., Whitehouse Station, NJ
Background/Purpose: Patients with autoimmune diseases are often immunocompromised, resulting in higher incidence of HZ than in immunocompetent individuals with significant morbidity and occasional mortality from…
Abstract Number: 138 • 2013 ACR/ARHP Annual Meeting
Long Term Outcomes In Fibromyalgia
Lesley M. Arnold¹ and Thomas Blom², ¹Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, ²Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH
Background/Purpose: There are few studies on the long-term prognosis of fibromyalgia. This study assessed the natural history of fibromyalgia in patients receiving usual medical care…
Abstract Number: 2544 • 2013 ACR/ARHP Annual Meeting
Serum Mediated Phagocytosis Of Necrotic Material By Polymorphonuclear Leukocytes May Be Used As a Tool To Predict Clinical Manifestations In Systemic Lupus Erythematosus
Michele Compagno¹, Birgitta Gullstrand², Andreas Jönsen³, Lennart Truedsson², Gunnar Sturfelt⁴ and Anders A. Bengtsson³, ¹Department of clinical sciences - Rheumatology, Lund University, Lund, Sweden, ²Department of Laboratory Medicine, Section of Microbiology, Immunology and Glycobiology, Lund University, Lund, Sweden, ³Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden, ⁴Department of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund, Sweden
Background/Purpose: Polymorphonuclear (PMNs) leukocytes with engulfed necrotic cell material (NCM), as formerly used in the LE-cell test, are frequently seen in SLE and associated to…
Abstract Number: 2286 • 2013 ACR/ARHP Annual Meeting
Reliability and Smallest Detectable Difference Of The Patient Global Assessment, Pain and Fatigue In Rheumatoid Arthritis Patients
Paul Studenic¹, Josef S. Smolen^2,3 and Daniel Aletaha⁴, ¹Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²PsAID taskforce, EULAR, Zurich, Switzerland, ³2nd Department of Medicine, Krankenhaus Lainz, Vienna, Austria, ⁴Department of Internal Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Austria
Background/Purpose: Patient reported outcomes (PRO) represent an important part of outcomes assessment in rheumatoid arthritis (RA) patients. The Patient Global Assessment (PGA) is an essential…
Abstract Number: 2050 • 2013 ACR/ARHP Annual Meeting
Arthralgia Occurring Under Aromatase Inhibitor Treatment For Breast Cancer. A Prospective Study
Daniel Wendling¹, Helene Letho-Gyselinck¹, Xavier Guillot², Clément Prati³ and Xavier Pivot⁴, ¹Service de Rhumatologie, Minjoz University Hospital, Besancon, France, ²Department of Rheumatology, CHRU Besançon, Besançon, France, ³Service de Rhumatologie, CHU J Minjoz, Besancon, France, ⁴Oncology, CHRU Besançon, Besançon, France
Background/Purpose: Treatment with third generation aromatase inhibitors (AI) is associated with occurrence of arthralgia, with an incidence ranging from 25 to 45 %. In these…
Abstract Number: 1925 • 2013 ACR/ARHP Annual Meeting
Patient Satisfaction with an Associate Teaching Hospital Clinical Trial Unit In North-East London
Genevieve Casey¹, Carey Tierney², Hasan Tahir³, Simon Donnelly³ and Judith Bubbear³, ¹Barts and the London Medical School, London, United Kingdom, ²Whipps Cross Clinical Research Unit, Barts Health NHS Trust, London, United Kingdom, ³Rheumatology, Barts Health NHS Trust, London, United Kingdom
Background/Purpose: Compared to patient satisfaction with general medical care little is known about patient satisfaction within clinical trials. Clinical trials are a time and resource…
Abstract Number: 1526 • 2013 ACR/ARHP Annual Meeting
Stable Clinical and MRI Response In Patients With Early Axial Spondyloarthritis After 3 Years Of Continuous Treatment With Etanercept, Data Of The Esther Trial
In-Ho Song¹, Kay-Geert A. Hermann², Hildrun Haibel¹, Christian Althoff³, Denis Poddubnyy⁴, Joachim Listing⁵, Anja Weiss⁶, Ekkehard Lange⁷, Bruce Freundlich⁸, Martin Rudwaleit⁹ and Joachim Sieper⁴, ¹Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany, ²Radiology, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, ³Radiology, Charite Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, ⁴Charité Universitätsmedizin Berlin, Berlin, Germany, ⁵German Rheumatism Research Center, Berlin, Germany, ⁶German Rheumatism Research Centre, Berlin, Germany, ⁷BU Specialty Care, Pfizer Pharma AG, Berlin, Germany, ⁸University of Pennsylvania, Philadelphia, PA, ⁹Endokrinologikum, Berlin, Germany
Background/Purpose: < style="text-align: justify;">In patients with early axial spondyloarthritis (SpA) with a disease duration of 10 years) where BASDAI50 response rates of 47%…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].